President Trump Loaded Up on Eli Lilly in Q1. Should You Buy the Obesity Drug Stock Too?

Eli Lilly generated roughly $65 billion in 2025 revenue, with Mounjaro and Zepbound combined sales topping $30 billion as obesity drugs remain in an early-stage market that could exceed $95 billion annually and potentially reach $200 billion. Analysts expect earnings to rise from about $23 per share in 2025 to roughly $37-$52 per share over the next four years, supported by manufacturing expansion and next-generation obesity treatments. The article is constructive on Lilly’s fundamentals but notes valuation risk and rising competition from Novo Nordisk, Viking Therapeutics, Amgen, Roche, and others.

Analysis

The key second-order effect is that this is no longer just a demand story; it is becoming a manufacturing and distribution moat story. In obesity, capacity constraints are effectively a tax on growth, so the winner is not necessarily the molecule with the best headline efficacy, but the company that can convert prescriptions into filled units at scale without channel friction. That favors LLY over NVO near term and makes smaller developers like VKTX more relevant as M&A or partnership optionality rather than stand-alone commercial threats.

Consensus is still underestimating how long the market can stay structurally underpenetrated even if competition intensifies. The addressable pool is large enough that a few years of share loss do not automatically break the bull case; the real risk is valuation compression if investors start treating this like a normal pharma franchise instead of a platform with secular penetration expansion. In that scenario, a single disappointment in manufacturing execution or reimbursement could trigger a multi-turn multiple reset even if the revenue line keeps growing.

A more contrarian takeaway is that the crowded long is not just LLY — it is the entire obesity complex. As capital floods into next-generation names, the market may be overpaying for pipeline optionality while underpricing the incumbents’ ability to extend exclusivity through formulation, device, and lifecycle management. That makes LLY/NVO the cleaner relative-value expression, while pure-play development names likely need clinical de-risking before re-rating can persist.

Catalyst timing matters: this is a months-to-years trade, not a one-day headline trade. Near-term upside likely depends on evidence that volume can outgrow supply expansion and payer pushback; downside comes if prescription growth decelerates, competitors narrow access gaps, or pricing pressure emerges in the next 2-3 quarters. For holders, the risk is not business deterioration so much as expectations outrunning the normalization of growth rates.

Key Decisions for Investors

• Maintain a core long LLY, but size it as a quality-growth compounder rather than a momentum trade; use 3-6 month pullbacks to add, since the primary risk is multiple compression, not thesis failure.
• Pair trade: long LLY / short NVO for the next 6-12 months to express relative execution and manufacturing advantage; this targets share-gain dispersion rather than absolute sector beta.
• Speculative basket: long VKTX only as a call-option-style position sized small, with the thesis that any partnership/M&A premium is the main monetization path; trim into strength ahead of clinical binary events.
• If owning LLY outright, consider selling upside calls 6-9 months out against the position to harvest elevated implied volatility while preserving core exposure to the secular obesity rollout.
• Avoid chasing the obesity group indiscriminately; prefer LLY over the broader healthcare basket, because the market is rewarding the theme twice — once for growth and again for scarcity — which makes lower-quality entrants vulnerable to a sharp de-rating.